CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 244 enrolled
Drug / intervention
insulin detemir +1 moredrug
Likely dose
insulin detemir 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00634842
NCT00634842Phase 4Completed
CompareCT.gov

Effect of Two Different Fasting Blood Glucose Titration Targets in Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily in Combination With 1-3 Oral Agents

Novo Nordisk A/S·interventional·Posted Mar 13, 2008·Updated Mar 10, 2017

In Brief

A Phase 4 clinical trial evaluating insulin detemir for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 244 participants across 69 sites in 2 countries.

Detailed Summary

This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do dose adjustments themselves.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2008
Enrollment StartFeb 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.3 years ago

Interventions

insulin detemirdrug

Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL

insulin detemirdrug

Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL